Introduction
Luteal Phase Support (LPS) refers to the pharmacological administration of progesterone — and in selected cases adjunct agents — to ensure adequate endometrial receptivity and sustain early pregnancy following assisted reproductive technology (ART).
1. Indications for Luteal Phase Support
1.1 Absolute (Non-Optional) Indications
- IVF/ICSI fresh stimulated cycles (GnRH antagonist protocol / GnRH agonist long protocol)
- Hormonally programmed (artificial) FET cycles
- Donor oocyte and gestational surrogate cycles
- GnRH agonist trigger cycles (instead of hCG)
1.2 Selective / Debated Indications
- True natural cycle FET — routine LPS is not universally required; supplementation is considered if mid-luteal serum P4 falls below 10 ng/mL
- Modified natural cycle FET (hCG trigger) — post-trigger corpus luteum function may be supplemented empirically with vaginal progesterone, though evidence of benefit is not conclusive
- Unexplained recurrent implantation failure (RIF) or suspected luteal phase defect — progesterone supplementation is frequently used empirically, though the diagnosis of “luteal phase deficiency” remains contested
2. Pharmacological Agents for LPS
Key pharmacological actions of progesterone in the context of LPS include: endometrial secretory transformation, uterine quiescence, immunological tolerance, cervical mucus thickening, neuroendocrine feedback, and decidualization.
2.1 Natural Micronized Progesterone (NMP)
Natural micronized progesterone (NMP) is bioidentical to endogenous progesterone and binds both progesterone receptor isoforms (PR-A and PR-B) with equal affinity via classical genomic pathways.
2.2 Dydrogesterone
Dydrogesterone is a retroprogesterone — a stereoisomer of progesterone with an inverted C9,10 bond configuration. This structural change confers three clinically important properties: high oral bioavailability, near-complete selectivity for progesterone receptors, and minimal blood–brain barrier penetration.
Synthetic progestins differ substantially in receptor selectivity, pharmacokinetics, and suitability for ART. Understanding their profiles is essential to avoid inappropriate use:
| Compound | PR | AR | GR / MR | Role in ART |
|---|---|---|---|---|
| Dydrogesterone | High (PR-A/B) | None | None / None | First-line oral LPS — guideline endorsed |
| NMP (micronized) | High | None | None / None | First-line vaginal / IM / SC LPS |
| Hydroxyprogesterone caproate (HPC) | Moderate | None | Weak / None | IM LPS in selected protocols; FDA-approved for PTL |
Medroxyprogesterone acetate (MPA), norethisterone (NET), and levonorgestrel are not used for ART LPS.
LOTUS I & LOTUS II Trials
The landmark Phase III LOTUS I trial (Tournaye et al., 2017) demonstrated non-inferiority of dydrogesterone 10 mg three times daily versus vaginal micronized progesterone 200 mg three times daily for ongoing pregnancy rates at 12 weeks in fresh embryo transfer cycles. LOTUS II confirmed equivalent efficacy in FET cycles. Dydrogesterone is now formally endorsed by ESHRE as a guideline-recommended oral alternative to vaginal progesterone.
3. Routes of Administration
Route selection significantly affects pharmacokinetics, endometrial progesterone exposure, patient tolerability, and cycle outcomes. Clinical decisions must integrate cycle type, OHSS risk, patient preference, and serum progesterone monitoring data.
| Route | Examples | Serum P4 | Key Advantage | Key Limitation |
|---|---|---|---|---|
| Vaginal | Utrogestan 200 mg, Crinone 8% gel | Moderate; uterine first-pass ↑ | Direct uterine delivery; highest endometrial tissue concentration; avoids first-pass liver metabolism | Vaginal discharge; local irritation; poor patient satisfaction in some |
| Intramuscular (IM) | Progesterone in oil (PIO) 50 mg/mL | High, sustained (t½ ~28 h) | Highest and most predictable serum levels; extensive RCT evidence base | Painful injections; oil vehicle reactions; rare oil embolism; injection site nodules |
| Oral | Dydrogesterone 10 mg; NMP 200 mg (Prometrium) | Dydrogesterone: good; NMP oral: variable | High convenience; excellent compliance; no local side-effects | NMP oral: heavy sedation/drowsiness; dydrogesterone strongly preferred orally |
| Subcutaneous (SC) | Prolutex 25 mg aqueous injection | Moderate-high; sustained | Easy self-injection; no oil vehicle; minimal injection site reactions | Less globally available; injection site bruising; less long-term data than IM/vaginal |
3.1 The Uterine First-Pass Effect (Ashley–Cicinelli Effect)
Vaginally administered progesterone exploits counter-current exchange between the uterine artery and uterine/vaginal venous plexuses, creating a progesterone concentration gradient that delivers 10–40 times the systemic serum concentration directly to the endometrium. This is the Ashley–Cicinelli uterine first-pass effect.
Clinical Implication
Serum progesterone levels substantially underestimate endometrial exposure when the vaginal route is used. Clinicians should not discontinue vaginal therapy solely on the basis of a “low” serum level without first evaluating the adequacy of dosing and considering switching to IM or SC routes if concern persists.
4. Serum Progesterone (P4) Measurement Before Embryo Transfer
Fresh Embryo Transfer
Unlike HRT-FET cycles, where progesterone is entirely exogenous and monitoring is increasingly recommended, the evidence for routine progesterone measurement after oocyte retrieval and before fresh transfer is less robust. The progesterone measurement that is universally accepted in fresh IVF is progesterone on trigger day (before hCG/GnRH agonist trigger), rather than progesterone after retrieval.
| Trigger-Day P4 | Interpretation |
|---|---|
| >1.0 ng/mL | Possible concern |
| >1.5 ng/mL | Most commonly used threshold |
| >2.0 ng/mL | Significant elevation |
Many clinics consider a freeze-all strategy when trigger-day P4 exceeds 1.5–2.0 ng/mL.
Frozen Embryo Transfer — HRT / Programmed / Natural Cycle
≥10 ng/mL (≈31.8 nmol/L) is generally considered the minimum acceptable serum progesterone level. Levels <10 ng/mL on the day before or day of transfer are associated with lower implantation, clinical pregnancy, and live birth rates.
| Serum Progesterone (ng/mL) | Interpretation |
|---|---|
| <8 | Clearly suboptimal; supplementation usually considered |
| 8–10 | Borderline |
| 10–15 | Acceptable / Target range |
| >15–20 | Generally reassuring |
| >30 | Common with IM progesterone; not usually concerning |
The threshold varies with the route used (vaginal vs. IM progesterone), natural vs. artificial cycle, and timing of blood draw relative to progesterone administration.
5. Clinical Dosing Protocols by Cycle Type
| Cycle Type | Preferred Agent | Dose & Route | Start & Duration | Alternative / Escalation |
|---|---|---|---|---|
| IVF/ICSI Fresh — GnRH Agonist (long) protocol | NMP vaginal | Utrogestan 200 mg TDS vaginally | Day of oocyte retrieval → 10–12 weeks gestation; taper over 1–2 weeks | Add IM PIO 50 mg/day if serum P4 <10 ng/mL at transfer |
| IVF/ICSI Fresh — GnRH Antagonist protocol | NMP vaginal or dydrogesterone oral | 200 mg TDS vaginally OR dydrogesterone 10 mg TDS orally | Day of retrieval → 8–10 weeks gestation | Dydrogesterone 10 mg TDS oral — equivalent efficacy; better compliance |
| Programmed (artificial) FET | NMP vaginal ± IM PIO | Utrogestan 200 mg TDS or Crinone 8% BD vaginally ± PIO 50 mg IM if needed | 5–6 days before embryo transfer → 10 weeks; no taper before 8 weeks | Switch to or add IM PIO 50 mg daily if serum P4 inadequate |
| Natural cycle FET | None routinely; NMP if P4 low | Only if serum P4 <10 ng/mL: add vaginal NMP 200 mg BD | From ovulation day → 8–10 weeks gestation | — |
| GnRH agonist trigger + fresh transfer | Intensive dual: IM + vaginal NMP | PIO 50 mg IM daily + Utrogestan 200 mg TDS vaginally ± hCG 1500 IU SC (rescue dose) | Day of retrieval → βhCG positive; then reassess with serum P4 | + low-dose hCG 1500 IU SC rescue on day of retrieval |
| Donor oocyte / gestational surrogate | NMP vaginal (± IM if inadequate) | Utrogestan 200 mg TDS; commence when endometrial thickness ≥7 mm after E2 priming | Until 10–12 weeks; gradual taper thereafter | Add IM PIO if P4 borderline; continue strictly to 12 weeks |
| Recurrent implantation failure (RIF) | Combination: vaginal + IM | NMP 200 mg TDS vaginally + PIO 50 mg IM every 2–3 days | Start 5–6 days before transfer → 12 weeks | Multidisciplinary review; consider steroids / aspirin in selected immune cases |
6. Serum Progesterone Monitoring and Its Significance
Serum progesterone monitoring on the day of embryo transfer (ET-P4) or a day before has emerged as an important prognostic marker. A pivotal meta-analysis (Melo et al., 2021) demonstrated that an ET-P4 below 9.2 ng/mL on the day of transfer was independently associated with a significantly lower ongoing pregnancy rate, regardless of embryo quality or endometrial thickness.
| Route | Suggested Serum P4 Target | Action if Below Threshold |
|---|---|---|
| Vaginal NMP | >9–10 ng/mL on transfer day | Do NOT simply increase vaginal dose further. Switch to or add IM PIO 50 mg/day or SC progesterone — the uterine first-pass effect makes vaginal dose escalation inefficient for raising serum levels. |
| IM Progesterone in Oil | >20 ng/mL on transfer day | If below threshold: increase injection frequency (e.g., daily instead of alternate days) or add vaginal NMP. |
| SC Aqueous Progesterone | >10–15 ng/mL | Increase dose or frequency; can combine with vaginal NMP for enhanced endometrial exposure. |
| Oral Dydrogesterone | Serum P4 not a reliable marker (different metabolism) | Serum P4 does not reflect dydrogesterone efficacy. Monitor clinical outcomes; switch route only if implantation failure recurs. |
The 2021 ESHRE Position Statement on individualized luteal phase support recommends mid-luteal serum P4 measurement (day of transfer or 3–5 days post-transfer) and route adjustment in vaginal progesterone users. This “personalized LPS” concept represents a significant paradigm shift from fixed-dose protocols to outcome-guided supplementation.
7. Non-Progesterone Adjunct Agents
While progesterone remains the cornerstone of LPS, several adjunct agents have been investigated — either as luteal stimulants or endometrial modulators — in specific clinical contexts. Their evidence base and current guideline status are summarized below:
| Agent | Mechanism | Dose & Timing | Evidence & ESHRE 2025 Status |
|---|---|---|---|
| Estradiol (E2) | Endometrial proliferative support; corrects luteal E2 deficiency | 2 mg BD–TDS oral or 100–200 mcg transdermal patch; from retrieval to pregnancy test | Multiple meta-analyses show no improvement in live birth or clinical pregnancy rates when added to progesterone. ESHRE 2025: probably not recommended as routine adjunct. |
| Low-dose hCG | LH-receptor stimulation → corpus luteum rescue; endogenous steroid production | 1500 IU SC on day of retrieval in GnRH agonist trigger cycles only | Useful adjunct after GnRH agonist trigger. Standard-dose hCG for routine LPS in hCG-triggered cycles: NOT recommended (OHSS risk outweighs benefit). |
| GnRH Agonist (triptorelin/leuprolide) | Stimulates pituitary LH surge; putative direct embryonic effect | Triptorelin 0.1 mg SC single bolus on day 6 post-retrieval | Inconsistent RCT results; possible benefit in RIF. ESHRE 2025: not routinely recommended. |
| Corticosteroids | — | Prednisolone 5–20 mg/day or dexamethasone 0.5–2 mg/day from stimulation start | No RCT evidence in unselected patients. Considered empirically in elevated uterine NK-cell protocols and autoimmune implantation failure. Not routinely recommended. |
| Low-dose Aspirin | Improves uterine artery blood flow; anti-platelet/anti-thrombotic | 75–100 mg/day orally; start before stimulation or transfer | Meta-analyses show no improvement in live birth rates in unselected IVF patients. Indicated for APS and thrombophilia-associated infertility. ESHRE & ASRM: not recommended routinely for LPS. |
| Recombinant LH (lutropin alfa) | Direct luteotropic support via LH receptor | 75 IU SC daily from retrieval; limited data | Insufficient evidence. Very expensive. ESHRE 2025: use only within clinical trials; routine use not recommended. |
8. Duration of LPS and Weaning Strategy
The duration of LPS is governed by the concept of the luteo-placental shift — the transition of progesterone synthesis from the corpus luteum to the developing trophoblast/placenta, which occurs between 7–10 weeks of gestation. Until this shift is complete, the embryo and early placenta are not capable of independent steroidogenesis and are entirely reliant on exogenous progesterone supplementation in ART cycles.
Duration Summary
- Continue LPS until 10–12 weeks gestation in fresh IVF/ICSI, programmed FET, donor egg, and GnRH-agonist trigger cycles (with gradual taper over 1–2 weeks).
- In natural-cycle FET with supplementation for low progesterone, LPS can usually be stopped at 7–8 weeks after confirmation of a viable intrauterine pregnancy.
- Routine extension beyond 12 weeks is not evidence-based, except in selected high-risk cases.
- In programmed FET cycles where the corpus luteum is entirely absent, premature discontinuation of progesterone — even by a few days — can precipitate biochemical pregnancy loss. Patients must be counselled rigorously about compliance.
Key References
- ESHRE Guideline: Ovarian Stimulation for IVF/ICSI (2019, updated 2025). European Society of Human Reproduction and Embryology.
- Fatemi HM, Popovic-Todorovic B. Luteal phase support in IVF cycles: current evidence and future perspectives. Human Reproduction Update 2007; 13(5):581–590.
- Glujovsky D, et al. Endometrial preparation for women undergoing embryo transfer with frozen embryos or embryos derived from donor oocytes. Cochrane Database Syst Rev 2017; 6:CD006359.
- Paulson RJ. Hormonal induction of endometrial receptivity. Fertility and Sterility 2011; 96(3):530–535.
- Cicinelli E, et al. Progesterone administration by vaginal route: uterine first-pass effect. Human Reproduction 2000; 15(12):2591–2595.
- Penzias AS. Luteal phase support. Fertility and Sterility 2002; 77(2):318–323.
- Diedrich K, et al. The role of the endometrium and embryo in human implantation. Human Reproduction Update 2007; 13(4):365–377.
- Fatemi HM, et al. An update of luteal phase support in stimulated IVF cycles. Human Reproduction Update 2007; 13(6):581–590.
- Melo P, et al. Serum progesterone on the day of embryo transfer as a predictor of IVF outcome: a systematic review and meta-analysis. EJOG & Reproductive Biology 2021; 257:125–132.
- van der Linden M, et al. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev 2015; 7:CD009154.
- Lockwood G, Griesinger G, Cometti B. Subcutaneous progesterone versus vaginal progesterone gel for luteal phase support in IVF: a prospective RCT. Fertility and Sterility 2014; 101(1):112–119.
- Pouly JL, et al. Luteal support after in-vitro fertilization: Crinone 8% versus Utrogestan. Human Reproduction 1996; 11(10):2085–2089.
- Barbosa MWP, et al. Dydrogesterone versus progesterone for luteal-phase support: a systematic review and meta-analysis. JARG 2016; 33(4):473–481.
- Tournaye H, et al. A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in IVF (LOTUS I). Human Reproduction 2017; 32(5):1019–1027.
- Practice Committee of ASRM. Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: educational bulletin. Fertility and Sterility 2008; 90(5 Suppl): S150–S153.
Have Questions About Your LPS Protocol?
Our fertility specialists at Valencia IVF personalize luteal phase support for every patient based on cycle type and hormone monitoring.